Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Elanco Animal Health turns veterinary science into revenue isn’t easy—each 10-K details dozens of R&D pipeline assets, FDA approvals, and integration costs from the Bayer Animal Health acquisition. If you have ever asked, “Where can I read Elanco’s quarterly earnings report 10-Q filing?” or “How do I locate Elanco insider trading Form 4 transactions?” you already know the challenge.
Stock Titan solves it. Our AI-powered summaries translate the technical language in every Elanco SEC document into plain English, flagging segment margins, companion-animal growth, and farm-animal productivity trends. Receive real-time alerts the moment an Elanco Form 4 insider transactions real-time filing hits EDGAR, or open an Elanco 8-K material events explained card to see if a new parasiticide received FDA approval—all without wading through hundreds of pages.
Here’s what you can explore in seconds:
- Elanco annual report 10-K simplified—AI highlights pipeline updates, manufacturing efficiencies, and acquisition synergies.
- Elanco quarterly earnings report 10-Q filing—compare sequential companion-animal sales and R&D spend.
- Elanco proxy statement executive compensation—see how leadership incentives align with product launch milestones.
- Elanco executive stock transactions Form 4—monitor insider buying ahead of material announcements.
Whether you search “understanding Elanco SEC documents with AI” or need fast Elanco earnings report filing analysis, our platform keeps every filing type in one place, updated the moment Elanco submits it. Save hours, spot trends early, and make better calls on ELAN.
Elanco Animal Health director defers fees into stock units. Director Kapila K. Anand converted a portion of her cash director fees into deferred stock units under Elanco's Directors' Deferral Plan on December 31, 2025. She received 381.1312 Deferred Stock Units, each economically equivalent to one share of Elanco common stock, based on the closing share price of $22.63 on the grant date. Following this transaction, she held a total of 8,894.7414 deferred stock units, which will be settled in Elanco common stock when she separates from the Board of Directors.
Elanco Animal Health Inc. insider Jeffrey N. Simmons, the company’s President, CEO and Director, reported an acquisition of derivative securities in the form of deferred stock units on 12/26/2025. The filing shows he acquired 122.5327 deferred stock units tied to Elanco common stock at a derivative price of
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units are scheduled to settle in cash or shares of Elanco common stock after termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive reports deferred stock unit grant. On 12/26/2025, an officer of Elanco Animal Health Inc. acquired 62.5938 deferred stock units under the company’s Executive Deferral and Stock Match Plan. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. Following this transaction, the reporting person beneficially owned 7,420.0759 deferred stock units, which will settle in cash or shares after employment ends or in a specified future year. The officer’s title is Executive Vice President U.S. Pet Health and Global Digital Transformation.
Elanco Animal Health Inc director reports charitable stock gift. Director R. David Hoover reported a transaction dated 12/19/2025 involving Elanco common stock. The filing shows that a revocable trust associated with him disposed of 60,000 shares as a gift to a charitable trust at a reported price of $0 per share.
After this gift, he is shown as beneficially owning 150,000 shares indirectly through a revocable trust, 106,773 shares directly, and 15,920 shares indirectly through the Suzanne A. Hoover Revocable Trust. This reflects a shift in how part of his holdings are allocated, with shares redirected to charitable purposes while maintaining substantial ownership interests.
Elanco Animal Health Inc. director Lawrence Kurzius reported an open-market purchase of company stock. On 12/12/2025, he bought 10,000 shares of Elanco common stock at a price of $21.3 per share. Following this transaction, his directly held beneficial ownership increased to 131,773 shares of Elanco common stock. The filing indicates that it was submitted for one reporting person, reflecting Kurzius’s role as a director of the company.
Elanco Animal Health Inc. officer Rajeev A. Modi reported acquiring additional deferred stock units tied to the company’s common stock. On 12/12/2025, he acquired 66.4453 deferred stock units at a price of $21.29 per unit, increasing his directly held deferred stock units to 7,357.4821.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, with settlement following termination of employment or during a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health Inc. reported an insider equity transaction by its president, CEO and director, Jeffrey N. Simmons. On 12/12/2025 he acquired 130.0723 deferred stock units at $ 21.29 per unit, increasing his holdings to 18,604.9984 deferred stock units, held directly. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and these units settle in cash or shares following termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health executive Rajeev A. Modi, Executive Vice President U.S. Pet Health and Global Digital Transformation, reported an insider purchase of company stock. On December 11, 2025, he acquired 4,500 shares of Elanco common stock at a price of $21.33 per share.
After this transaction, Modi directly beneficially owns 123,082 Elanco shares. This total includes 1,579 shares acquired on January 31, 2025 and 205 shares acquired on April 30, 2025 under Elanco Animal Health Inc.'s Employee Stock Purchase Plan.
Elanco Animal Health Inc. executive Robert M. VanHimbergen, the company’s EVP and CFO, reported buying 6,950 shares of common stock on December 11, 2025. The shares were purchased at a weighted average price of $21.6441 per share, with individual trades executed between $21.60 and $21.70 per share.
Following this transaction, he beneficially owns 124,233 shares of Elanco common stock held directly. The reported balance includes 7,426 shares that were previously reported but inadvertently omitted from his prior reported holdings.
Elanco Animal Health Inc. President, CEO and Director Jeffrey N. Simmons reported buying 22,000 shares of Elanco common stock on December 11, 2025. The shares were purchased in multiple transactions at a weighted average price of $21.7498 per share, with individual trade prices ranging from $21.739 to $21.75.
After this transaction, Simmons beneficially owned 167,000 shares held indirectly through a revocable trust and 1,802,380 shares held directly. The direct holdings include 1 share acquired on April 30, 2025 under Elanco Animal Health Inc.'s Employee Stock Purchase Plan.
FAQ
What is the current stock price of Elanco Animal Health (ELAN)?
What is the market cap of Elanco Animal Health (ELAN)?
